Please log in to view this page
Username
Password
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
